Home LiteratureArticle Details
PMID: 19917708 Published · ppublish English Journal Article Review

Waging war against uropathogenic Escherichia coli: winning back the urinary tract.

Infection and immunity ·Vol. 78 ·No. 2 ·2010-02-00 ·Pages 568-85

Sivick KE, Mobley HL

Abstract

Urinary tract infection (UTI) caused by uropathogenic Escherichia coli (UPEC) is a substantial economic and societal burden-a formidable public health issue. Symptomatic UTI causes significant discomfort in infected patients, results in lost productivity, predisposes individuals to more serious infections, and usually necessitates antibiotic therapy. There is no licensed vaccine available for prevention of UTI in humans in the United States, likely due to the challenge of targeting a relatively heterogeneous group of pathogenic strains in a unique physiological niche. Despite significant advances in the understanding of UPEC biology, mechanistic details regarding the host response to UTI and full comprehension of genetic loci that influence susceptibility require additional work. Currently, there is an appreciation for the role of classic innate immune responses-from pattern receptor recognition to recruitment of phagocytic cells-that occur during UPEC-mediated UTI. There is, however, a clear disconnect regarding how factors involved in the innate immune response to UPEC stimulate acquired immunity that facilitates enhanced clearance upon reinfection. Unraveling the molecular details of this process is vital in the development of a successful vaccine for prevention of human UTI. Here, we survey the current understanding of host responses to UPEC-mediated UTI with an eye on molecular and cellular factors whose activity may be harnessed by a vaccine that stimulates lasting and sterilizing immunity.

MeSH Terms
Animals Escherichia coli Escherichia coli Infections Humans Urinary Tract Infections/microbiology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Sivick Kelsey E
Department of Microbiology and Immunology, 5641 Medical Science Building II, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0620, USA.
Mobley Harry L T
References (292)
292 references, click to expand
  1. Localization of uroplakin Ia, the urothelial receptor for bacterial adhesin FimH, on the six inner domains of the 16 nm urothelial plaque particle.
    J Mol Biol. 2002 Apr 12;317(5):697-706 PMID: 11955018
  2. Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice.
    Infect Immun. 1984 Dec;46(3):839-44 PMID: 6389367
  3. A toll-like receptor that prevents infection by uropathogenic bacteria.
    Science. 2004 Mar 5;303(5663):1522-6 PMID: 15001781
  4. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections.
    Eur Urol. 2005 Apr;47(4):542-8; discussion 548 PMID: 15774256
  5. Identification of factors in human urine that inhibit the binding of Escherichia coli adhesins.
    Infect Immun. 1988 Oct;56(10):2623-30 PMID: 2901405
  6. Adhesion of piliated Escherichia coli strains to phagocytes: differences between bacteria with mannose-sensitive pili and those with mannose-resistant pili.
    Infect Immun. 1982 Jan;35(1):264-9 PMID: 6119294
  7. Adhesion, hemagglutination, and virulence of Escherichia coli causing urinary tract infections.
    Infect Immun. 1981 Feb;31(2):564-70 PMID: 7012012
  8. Flushing bacteria out of the bladder.
    Nat Med. 2007 May;13(5):531-2 PMID: 17479092
  9. Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB.
    Infect Immun. 2001 Nov;69(11):6689-95 PMID: 11598039
  10. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.
    Infect Immun. 1991 Mar;59(3):1153-61 PMID: 1671776
  11. Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies.
    J Biol Response Mod. 1990 Apr;9(2):231-40 PMID: 2160522
  12. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis.
    Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1333-8 PMID: 14739341
  13. Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection.
    J Immunol. 1987 May 15;138(10):3475-80 PMID: 3553327
  14. An "omics" approach to uropathogenic Escherichia coli vaccinology.
    Trends Microbiol. 2009 Oct;17(10):431-2 PMID: 19758805
  15. Activation of natural killer cells and cytokine production in man by bacterial extracts.
    Immunopharmacol Immunotoxicol. 1989;11(1):17-32 PMID: 2503554
  16. How pathogenic bacteria evade mammalian sabotage in the battle for iron.
    Nat Chem Biol. 2006 Mar;2(3):132-8 PMID: 16485005
  17. Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide.
    J Exp Med. 1989 Mar 1;169(3):1011-20 PMID: 2784476
  18. Generating memory with vaccination.
    Eur J Immunol. 2009 Aug;39(8):2100-5 PMID: 19637203
  19. Urologic diseases in America Project: analytical methods and principal findings.
    J Urol. 2005 Mar;173(3):933-7 PMID: 15711342
  20. Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway.
    J Biol Chem. 2009 Jan 2;284(1):446-454 PMID: 18996840
  21. Vaginal immunization against induced cystitis in monkeys.
    J Urol. 1987 Feb;137(2):327-9 PMID: 3543412
  22. Bacteriology and ultrastructure of the bladder in patients with urinary tract infections.
    J Infect. 1985 Nov;11(3):191-9 PMID: 3936879
  23. The structure of salmochelins: C-glucosylated enterobactins of Salmonella enterica.
    Biometals. 2004 Aug;17(4):471-81 PMID: 15259369
  24. Role of nitric oxide synthesis in macrophage antimicrobial activity.
    Curr Opin Immunol. 1991 Feb;3(1):65-70 PMID: 1711326
  25. Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli.
    J Biol Chem. 2002 Mar 1;277(9):7412-9 PMID: 11744708
  26. The demonstration of specific urinary anti-bodies in urinary tract infections caused by Gram-negative bacilli.
    J Pathol Bacteriol. 1966 Apr;91(2):589-95 PMID: 5331386
  27. Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection.
    J Urol. 1994 Dec;152(6 Pt 2):2308-11 PMID: 7966729
  28. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells.
    Urology. 2002 Sep;60(3):521-6 PMID: 12350510
  29. Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection.
    Cell Host Microbe. 2009 May 8;5(5):463-75 PMID: 19454350
  30. Interleukin-6 response of epithelial cell lines to bacterial stimulation in vitro.
    Infect Immun. 1992 Apr;60(4):1295-301 PMID: 1347759
  31. The effects of oral and combined parenteral/oral immunization against an experimental Escherichia coli urinary tract infection in mice.
    Clin Exp Immunol. 1983 Nov;54(2):305-12 PMID: 6360434
  32. Ultrastructural localization of lactoferrin and myeloperoxidase in human neutrophils by immunogold.
    Blood. 1985 Feb;65(2):423-32 PMID: 2981589
  33. TLR-mediated immune responses in the urinary tract.
    Curr Opin Microbiol. 2008 Feb;11(1):66-73 PMID: 18243043
  34. Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine.
    J Urol. 1994 Jan;151(1):214-6 PMID: 8254817
  35. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial.
    J Urol. 1990 Apr;143(4):759-62; discussion 762-3 PMID: 2179584
  36. Genetic factors in host resistance to urinary tract infection.
    Infection. 1984 Mar-Apr;12(2):118-23 PMID: 6376364
  37. Kinetics of cellular responses to intraperitoneal Brugia pahangi infections in normal and immunodeficient mice.
    Infect Immun. 2003 Aug;71(8):4361-7 PMID: 12874313
  38. Expression of type 1 fimbriae may be required for persistence of Escherichia coli in the catheterized urinary tract.
    J Clin Microbiol. 1987 Dec;25(12):2253-7 PMID: 2892855
  39. Iron transport and signaling in Escherichia coli.
    FEBS Lett. 2002 Oct 2;529(1):78-85 PMID: 12354617
  40. Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli.
    Nat Med. 2001 Jul;7(7):801-6 PMID: 11433344
  41. Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection.
    J Clin Invest. 1997 Sep 1;100(5):1123-36 PMID: 9276729
  42. Iron in innate immunity: starve the invaders.
    Curr Opin Immunol. 2009 Feb;21(1):63-7 PMID: 19231148
  43. Role of type 1 fimbria- and P fimbria-specific adherence in colonization of the neurogenic human bladder by Escherichia coli.
    Infect Immun. 2002 Nov;70(11):6481-4 PMID: 12379733
  44. Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis.
    J Am Soc Nephrol. 2004 Mar;15(3):613-21 PMID: 14978163
  45. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections.
    Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9630-5 PMID: 8790381
  46. Macrophage inflammatory protein-2 is required for neutrophil passage across the epithelial barrier of the infected urinary tract.
    J Immunol. 1999 Mar 1;162(5):3037-44 PMID: 10072556
  47. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration.
    Structure. 2005 Jan;13(1):29-41 PMID: 15642259
  48. Interleukin 8 receptor deficiency confers susceptibility to acute experimental pyelonephritis and may have a human counterpart.
    J Exp Med. 2000 Sep 18;192(6):881-90 PMID: 10993918
  49. Invariant NKT cells amplify the innate immune response to lipopolysaccharide.
    J Immunol. 2007 Mar 1;178(5):2706-13 PMID: 17312112
  50. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection.
    Nat Med. 2006 Jun;12(6):636-41 PMID: 16751768
  51. Cutting edge: Tlr5-/- mice are more susceptible to Escherichia coli urinary tract infection.
    J Immunol. 2007 Apr 15;178(8):4717-20 PMID: 17404249
  52. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.
    N Engl J Med. 1997 Apr 10;336(15):1066-71 PMID: 9091804
  53. Antibodies in Escherichia coli urinary tract infection.
    Proc Eur Dial Transplant Assoc. 1977;14:535-40 PMID: 341144
  54. Mucosal immunity: The origin and migration patterns of cells in the secretory system.
    J Allergy Clin Immunol. 1980 Jan;65(1):12-9 PMID: 6153083
  55. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells.
    EMBO J. 2000 Jun 15;19(12):2803-12 PMID: 10856226
  56. Survival of FimH-expressing enterobacteria in macrophages relies on glycolipid traffic.
    Nature. 1997 Oct 9;389(6651):636-9 PMID: 9335508
  57. Siderophores: structure and function of microbial iron transport compounds.
    J Biol Chem. 1995 Nov 10;270(45):26723-6 PMID: 7592901
  58. Tamm-Horsfall protein or uromucoid is the normal urinary slime that traps type 1 fimbriated Escherichia coli.
    Lancet. 1980 Apr 19;1(8173):887 PMID: 6103253
  59. FimH-mediated Escherichia coli K1 invasion of human brain microvascular endothelial cells.
    Cell Microbiol. 2007 Jan;9(1):169-78 PMID: 17222190
  60. Prevention of recurrent urinary tract infections in postmenopausal women.
    Nephron. 1988;50(1):24-7 PMID: 3173598
  61. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism.
    J Immunol. 2001 Jan 15;166(2):1148-55 PMID: 11145696
  62. FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling.
    PLoS Pathog. 2008 Dec;4(12):e1000233 PMID: 19057665
  63. TLR4-mediated expulsion of bacteria from infected bladder epithelial cells.
    Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14966-71 PMID: 19706440
  64. Control of recurrent lower urinary tract infection in the postmenopausal woman.
    J Urol. 1982 Dec;128(6):1224-6 PMID: 6296464
  65. Bacteria-induced uroplakin signaling mediates bladder response to infection.
    PLoS Pathog. 2009 May;5(5):e1000415 PMID: 19412341
  66. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.
    J Infect Dis. 2000 Feb;181(2):774-8 PMID: 10669375
  67. TLR11 activation of dendritic cells by a protozoan profilin-like protein.
    Science. 2005 Jun 10;308(5728):1626-9 PMID: 15860593
  68. Avian pathogenic, uropathogenic, and newborn meningitis-causing Escherichia coli: how closely related are they?
    Int J Med Microbiol. 2007 Jun;297(3):163-76 PMID: 17374506
  69. Uropathogenic Escherichia coli and tolerance to nitric oxide: the role of flavohemoglobin.
    J Urol. 2006 Feb;175(2):749-53 PMID: 16407044
  70. Induction of gene expression in Escherichia coli after pilus-mediated adherence.
    Science. 1996 Aug 30;273(5279):1234-6 PMID: 8703059
  71. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains.
    Infect Immun. 1998 Jun;66(6):2798-802 PMID: 9596750
  72. Vaginal immunization against urinary tract infection.
    J Urol. 1982 Dec;128(6):1382-4 PMID: 6759690
  73. Nitric oxide regulates endocytosis by S-nitrosylation of dynamin.
    Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1295-300 PMID: 16432212
  74. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl alpha-D-mannopyranoside.
    J Infect Dis. 1979 Mar;139(3):329-32 PMID: 376757
  75. Pathogenic Escherichia coli.
    Nat Rev Microbiol. 2004 Feb;2(2):123-40 PMID: 15040260
  76. Origins and virulence mechanisms of uropathogenic Escherichia coli.
    Exp Mol Pathol. 2008 Aug;85(1):11-9 PMID: 18482721
  77. Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.
    Clin Microbiol Rev. 2005 Apr;18(2):264-92 PMID: 15831825
  78. Phase variation of type 1 fimbriae in Escherichia coli is under transcriptional control.
    Science. 1981 Oct 16;214(4518):337-9 PMID: 6116279
  79. Functional heterogeneity of type 1 fimbriae of Escherichia coli.
    Infect Immun. 1992 Nov;60(11):4709-19 PMID: 1356930
  80. [Treatment with low-dose vaginal estradiol in post-menopausal women. A double-blind controlled trial].
    Ugeskr Laeger. 1990 Mar 5;152(10):658-9 PMID: 2181748
  81. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism.
    J Clin Invest. 2005 Feb;115(2):468-75 PMID: 15650774
  82. Variable adherence to normal human urinary-tract epithelial cells of Escherichia coli strains associated with various forms of urinary-tract infection.
    Lancet. 1976 Sep 4;1(7984):490-2 PMID: 74461
  83. Biological activity of bacterial cell-wall components: immunogenicity of the bacterial extract OM-89.
    Immunopharmacology. 1995 Feb;29(1):29-36 PMID: 7768669
  84. A mucoprotein derived from human urine which reacts with influenza, mumps, and Newcastle disease viruses.
    J Exp Med. 1952 Jan;95(1):71-97 PMID: 14907962
  85. Colonization with and acquisition of uropathogenic Escherichia coli as revealed by polymerase chain reaction-based detection.
    J Infect Dis. 1998 Apr;177(4):1120-4 PMID: 9534997
  86. Elevation of secretory IgA antibodies in the urinary tract by immunostimulation for the pre-operative treatment and post-operative prevention of urinary tract infections.
    Urol Int. 1987;42(6):424-6 PMID: 3448808
  87. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding.
    J Cell Sci. 2001 Nov;114(Pt 22):4095-103 PMID: 11739641
  88. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity.
    Cell Microbiol. 2008 Dec;10(12):2568-78 PMID: 18754853
  89. Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli.
    PLoS Pathog. 2007 Jul;3(7):e100 PMID: 17630833
  90. The uroepithelium: not just a passive barrier.
    Traffic. 2004 Mar;5(3):117-28 PMID: 15086788
  91. Secretory immunoglobulin A and inhibitory activity of bacterial adherence to epithelial cells in urine from patients with urinary tract infections.
    Urol Res. 1990;18(5):305-8 PMID: 2124012
  92. Clathrin, AP-2, and the NPXY-binding subset of alternate endocytic adaptors facilitate FimH-mediated bacterial invasion of host cells.
    Cell Microbiol. 2008 Dec;10(12):2553-67 PMID: 18754852
  93. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli.
    Infect Immun. 2002 Dec;70(12):7042-9 PMID: 12438384
  94. Passive immunization with antibodies against iron-regulated outer membrane proteins protects turkeys from Escherichia coli septicemia.
    Infect Immun. 1987 May;55(5):1239-42 PMID: 3552995
  95. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing.
    PLoS Biol. 2008 Nov 18;6(11):e280 PMID: 19018661
  96. IroN functions as a siderophore receptor and is a urovirulence factor in an extraintestinal pathogenic isolate of Escherichia coli.
    Infect Immun. 2002 Dec;70(12):7156-60 PMID: 12438401
  97. Synthetic peptides corresponding to protective epitopes of Escherichia coli digalactoside-binding pilin prevent infection in a murine pyelonephritis model.
    Proc Natl Acad Sci U S A. 1988 Feb;85(4):1247-51 PMID: 2448796
  98. Comparison of carbon nutrition for pathogenic and commensal Escherichia coli strains in the mouse intestine.
    Infect Immun. 2008 Mar;76(3):1143-52 PMID: 18180286
  99. Fine-tuning of T cell responses during infection.
    Curr Opin Immunol. 2009 Aug;21(4):367-77 PMID: 19646852
  100. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial.
    J Urol. 1997 Jun;157(6):2049-52 PMID: 9146577
  101. Treatment of bacterial infections of the female urinary tract by immunization of the patients.
    Urol Int. 1987;42(5):338-41 PMID: 3324441
  102. Synthesis of nitric oxide from L-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity.
    Res Immunol. 1991 Sep;142(7):565-9; discussion 596-8 PMID: 1812549
  103. Antibiotic resistance and pyelonephritis.
    Clin Infect Dis. 2007 Aug 1;45(3):281-3 PMID: 17599304
  104. Recurrent urinary tract infections.
    Best Pract Res Clin Obstet Gynaecol. 2005 Dec;19(6):861-73 PMID: 16298166
  105. Activation of natural killer T cells by alpha-galactosylceramide mediates clearance of bacteria in murine urinary tract infection.
    J Urol. 2005 Jun;173(6):2171-4 PMID: 15879881
  106. Basement membrane carbohydrate as a target for bacterial adhesion: binding of type I fimbriae of Salmonella enterica and Escherichia coli to laminin.
    Mol Microbiol. 1993 Jan;7(2):229-37 PMID: 8095317
  107. Gal-Gal binding and hemolysin phenotypes and genotypes associated with uropathogenic Escherichia coli.
    N Engl J Med. 1985 Aug 15;313(7):414-20 PMID: 2862582
  108. P fimbriae enhance the early establishment of Escherichia coli in the human urinary tract.
    Mol Microbiol. 2000 Nov;38(3):456-64 PMID: 11069670
  109. Identification of the leukocyte adhesion molecules CD11 and CD18 as receptors for type 1-fimbriated (mannose-specific) Escherichia coli.
    Infect Immun. 1991 Dec;59(12):4524-30 PMID: 1682263
  110. Fitness of Escherichia coli during urinary tract infection requires gluconeogenesis and the TCA cycle.
    PLoS Pathog. 2009 May;5(5):e1000448 PMID: 19478872
  111. Zipper-like internalization of Dr-positive Escherichia coli by epithelial cells is preceded by an adhesin-induced mobilization of raft-associated molecules in the initial step of adhesion.
    Infect Immun. 2004 Jul;72(7):3733-42 PMID: 15213113
  112. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women.
    JAMA. 1999 Feb 24;281(8):736-8 PMID: 10052444
  113. Congenital immunodeficiencies in mice increase susceptibility to urinary tract infection.
    J Urol. 1993 Apr;149(4):922-5 PMID: 8455276
  114. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract.
    J Am Soc Nephrol. 2007 Nov;18(11):2810-6 PMID: 17942949
  115. Bladder surface glycosaminoglycans is a human epithelial permeability barrier.
    Surg Gynecol Obstet. 1990 Dec;171(6):493-6 PMID: 2244283
  116. Origins and functions of B-1 cells with notes on the role of CD5.
    Annu Rev Immunol. 2002;20:253-300 PMID: 11861604
  117. Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization.
    Infect Immun. 2005 Nov;73(11):7657-68 PMID: 16239570
  118. Reaction of the vesical wall to bacterial penetration: resistance to attachment, desquamation, and leukocytic activity.
    Invest Urol. 1977 Nov;15(3):185-93 PMID: 591263
  119. Cell biology: iron thievery.
    Nature. 2004 Dec 16;432(7019):811-3 PMID: 15602535
  120. Transepithelial neutrophil migration is CXCR1 dependent in vitro and is defective in IL-8 receptor knockout mice.
    J Immunol. 2000 Nov 1;165(9):5287-94 PMID: 11046063
  121. Extrathymic origin of intestinal intraepithelial lymphocytes bearing T-cell antigen receptor gamma delta.
    Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):43-7 PMID: 1986381
  122. Innate immunity: the virtues of a nonclonal system of recognition.
    Cell. 1997 Oct 31;91(3):295-8 PMID: 9363937
  123. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition.
    Mol Cell. 2002 Nov;10(5):1033-43 PMID: 12453412
  124. Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections.
    Dev Biol Stand. 1998;92:117-22 PMID: 9554264
  125. Suppression of bladder epithelial cytokine responses by uropathogenic Escherichia coli.
    Infect Immun. 2005 Jul;73(7):3999-4006 PMID: 15972487
  126. Neutrophil recruitment and resistance to urinary tract infection.
    J Infect Dis. 1999 Oct;180(4):1220-9 PMID: 10479151
  127. Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication.
    Kidney Int. 2004 Mar;65(3):791-7 PMID: 14871399
  128. Local and systemic antibody responses accompany spontaneous resolution of experimental cystitis in cynomolgus monkeys.
    Infect Immun. 1987 Sep;55(9):1951-6 PMID: 3305357
  129. Iron metabolism at the host pathogen interface: lipocalin 2 and the pathogen-associated iroA gene cluster.
    Int J Biochem Cell Biol. 2007;39(10):1776-80 PMID: 17714976
  130. Type 1 fimbriae deliver an LPS- and TLR4-dependent activation signal to CD14-negative cells.
    Mol Microbiol. 2001 Feb;39(3):542-52 PMID: 11169097
  131. Cathelicidins, multifunctional peptides of the innate immunity.
    J Leukoc Biol. 2004 Jan;75(1):39-48 PMID: 12960280
  132. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.
    Nature. 2001 Apr 26;410(6832):1099-103 PMID: 11323673
  133. Glycogen and maltose utilization by Escherichia coli O157:H7 in the mouse intestine.
    Infect Immun. 2008 Jun;76(6):2531-40 PMID: 18347038
  134. Amino acid residue Ala-62 in the FimH fimbrial adhesin is critical for the adhesiveness of meningitis-associated Escherichia coli to collagens.
    Mol Microbiol. 1999 Mar;31(6):1747-57 PMID: 10209747
  135. Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4203-8 PMID: 12655047
  136. Gammadelta T cells: functional plasticity and heterogeneity.
    Nat Rev Immunol. 2002 May;2(5):336-45 PMID: 12033739
  137. Virulence factors in Escherichia coli urinary tract infection.
    Clin Microbiol Rev. 1991 Jan;4(1):80-128 PMID: 1672263
  138. Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4.
    Cell Microbiol. 2007 May;9(5):1239-51 PMID: 17223929
  139. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.
    N Engl J Med. 1993 Sep 9;329(11):753-6 PMID: 8350884
  140. Antigen 43, a phase-variable bipartite outer membrane protein, determines colony morphology and autoaggregation in Escherichia coli K-12.
    FEMS Microbiol Lett. 1997 Apr 1;149(1):115-20 PMID: 9103983
  141. Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli.
    Infect Immun. 2009 Jul;77(7):2762-72 PMID: 19451249
  142. UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli.
    J Bacteriol. 2008 Jun;190(12):4147-61 PMID: 18424525
  143. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues.
    J Clin Invest. 1998 Apr 15;101(8):1633-42 PMID: 9541493
  144. Antimicrobial peptides in innate immune responses.
    Contrib Microbiol. 2008;15:61-77 PMID: 18511856
  145. Enhancement of the bladder defense mechanism by immunization.
    Invest Urol. 1969 Mar;6(5):520-6 PMID: 4887493
  146. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms.
    J Biol Chem. 2009 Jan 9;284(2):711-5 PMID: 18757363
  147. Requirement of Rho-family GTPases in the invasion of Type 1-piliated uropathogenic Escherichia coli.
    Cell Microbiol. 2002 Jan;4(1):19-28 PMID: 11856170
  148. Differentiation-induced uroplakin III expression promotes urothelial cell death in response to uropathogenic E. coli.
    Microbes Infect. 2009 Jan;11(1):57-65 PMID: 19007907
  149. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
    Vaccine. 2008 Dec 9;26(52):6777-83 PMID: 18835576
  150. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach.
    Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5977-82 PMID: 16585510
  151. Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ- and cell-specific expression of Toll-like receptors within the human urinary tract.
    Cell Microbiol. 2001 Mar;3(3):153-8 PMID: 11260138
  152. Relationship between Escherichia coli strains causing acute cystitis in women and the fecal E. coli population of the host.
    J Clin Microbiol. 2008 Aug;46(8):2529-34 PMID: 18495863
  153. Conditioning of uropathogenic Escherichia coli for enhanced colonization of host.
    Infect Immun. 2009 May;77(5):2104-12 PMID: 19255192
  154. TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder.
    Cell Host Microbe. 2007 Jun 14;1(4):287-98 PMID: 17710226
  155. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury.
    Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):99-104 PMID: 15615857
  156. Targeting of immune signalling networks by bacterial pathogens.
    Nat Cell Biol. 2009 May;11(5):521-6 PMID: 19404331
  157. A structural comparison of human serum transferrin and human lactoferrin.
    Biometals. 2007 Jun;20(3-4):249-62 PMID: 17216400
  158. Decreased immunologic responsiveness following intensified vaginal immunization against urinary tract infection.
    J Urol. 1990 Jan;143(1):143-5 PMID: 2403596
  159. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial.
    Eur Urol. 1994;26(2):137-40 PMID: 7957468
  160. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial.
    J Infect Dis. 2001 Mar 1;183 Suppl 1:S81-3 PMID: 11171022
  161. The PapG tip adhesin of P fimbriae protects Escherichia coli from neutrophil bactericidal activity.
    Infect Immun. 1994 Dec;62(12):5296-304 PMID: 7960108
  162. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli.
    J Infect Dis. 2009 Jul 15;200(2):263-72 PMID: 19522648
  163. Local immunity and local immune responses.
    Prog Allergy. 1980;27:1-68 PMID: 6986045
  164. Approaching the asymptote? Evolution and revolution in immunology.
    Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:1-13 PMID: 2700931
  165. Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge.
    Can J Microbiol. 2006 Nov;52(11):1093-102 PMID: 17215901
  166. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women.
    Int J Antimicrob Agents. 1999 May;11(3-4):305-8 PMID: 10394988
  167. Identification of a type III secretion system in uropathogenic Escherichia coli.
    FEMS Microbiol Lett. 2002 Jul 2;212(2):221-8 PMID: 12113938
  168. Perspectives on mucosal vaccines: is mucosal tolerance a barrier?
    J Immunol. 2007 Nov 1;179(9):5633-8 PMID: 17947632
  169. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein.
    J Urol. 2004 Apr;171(4):1682-5 PMID: 15017266
  170. TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections.
    Eur J Clin Invest. 2008 Oct;38 Suppl 2:12-20 PMID: 18826477
  171. Urinary antibody response after immunisation with a vaccine against urinary tract infection.
    Urol Res. 1989;17(6):361-6 PMID: 2623792
  172. Antibody production in urinary bladder infection.
    Invest Urol. 1968 Sep;6(2):211-22 PMID: 4877423
  173. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.
    Science. 2002 Nov 1;298(5595):1025-9 PMID: 12411706
  174. The role of the epithelial cell in Escherichia coli induced neutrophil migration into the urinary tract.
    Eur Respir J. 1996 Aug;9(8):1713-28 PMID: 8866600
  175. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells.
    Nat Med. 2007 May;13(5):625-30 PMID: 17417648
  176. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract.
    Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14170-5 PMID: 16968784
  177. [Study on local immune response in Escherichia coli-induced experimental urinary tract infection in mice--infiltration of Ia-positive cells, macrophages, neutrophils, T cells and B cells].
    Kansenshogaku Zasshi. 1992 Jul;66(7):964-73 PMID: 1431374
  178. P fimbriae-dependent, lipopolysaccharide-independent activation of epithelial cytokine responses.
    Mol Microbiol. 1999 Aug;33(4):693-703 PMID: 10447879
  179. Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand.
    J Immunol. 2008 Nov 15;181(10):6702-6 PMID: 18981086
  180. Influence of Uro-Vaxom on sIgA level in urine in children with recurrent urinary tract infections.
    Arch Immunol Ther Exp (Warsz). 1996;44(2-3):195-7 PMID: 8915526
  181. Mammalian defensins in the antimicrobial immune response.
    Nat Immunol. 2005 Jun;6(6):551-7 PMID: 15908936
  182. Uroepithelial cells are part of a mucosal cytokine network.
    Infect Immun. 1994 Jun;62(6):2315-21 PMID: 8188354
  183. Bacterial adhesion and entry into host cells.
    Cell. 2006 Feb 24;124(4):715-27 PMID: 16497583
  184. Roles for accessory molecules in microbial recognition by Toll-like receptors.
    J Endotoxin Res. 2006;12(4):195-204 PMID: 16953972
  185. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.
    Science. 1998 Nov 20;282(5393):1494-7 PMID: 9822381
  186. Human cultured intestinal cells express attachment sites for uropathogenic Escherichia coli bearing adhesins of the Dr adhesin family.
    FEMS Microbiol Lett. 1994 Jun 1;119(1-2):27-32 PMID: 7913688
  187. Antigen-specific responses accelerate bacterial clearance in the bladder.
    J Immunol. 2006 Mar 1;176(5):3080-6 PMID: 16493067
  188. CD46 (membrane cofactor protein) acts as a human epithelial cell receptor for internalization of opsonized uropathogenic Escherichia coli.
    J Immunol. 2006 Aug 15;177(4):2543-51 PMID: 16888016
  189. Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice.
    Infect Immun. 1998 Jul;66(7):3059-65 PMID: 9632566
  190. Interleukin-8 and the neutrophil response to mucosal gram-negative infection.
    J Clin Invest. 1993 Aug;92(2):780-5 PMID: 8349817
  191. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus.
    Int Immunol. 1993 Jun;5(6):647-56 PMID: 8347558
  192. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.
    Vaccine. 2007 May 10;25(19):3859-70 PMID: 17306426
  193. How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains.
    Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12879-84 PMID: 16912116
  194. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection.
    Infect Immun. 2001 Jul;69(7):4572-9 PMID: 11402001
  195. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract.
    World J Urol. 1994;12(1):3-10 PMID: 8012413
  196. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem.
    Microbes Infect. 2003 Apr;5(5):449-56 PMID: 12738001
  197. Population-based epidemiologic analysis of acute pyelonephritis.
    Clin Infect Dis. 2007 Aug 1;45(3):273-80 PMID: 17599303
  198. Low dose oral estriol treatment in elderly women with urogenital infections.
    Acta Obstet Gynecol Scand Suppl. 1987;140:33-8 PMID: 3475935
  199. Urinary tract infections in women: diagnosis and treatment.
    Ann Intern Med. 1989 Dec 1;111(11):906-17 PMID: 2683922
  200. Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains.
    Int J Immunopharmacol. 2000 Jan;22(1):57-68 PMID: 10684989
  201. An electron microscopic study of the interaction between vesical epitherlium and E. Coli.
    Invest Urol. 1979 Jul;17(1):61-8 PMID: 376485
  202. Assessment of virulence of uropathogenic Escherichia coli type 1 fimbrial mutants in which the invertible element is phase-locked on or off.
    Infect Immun. 2002 Jul;70(7):3344-54 PMID: 12065472
  203. Reduction of bacteriuria and pyuria after ingestion of cranberry juice.
    JAMA. 1994 Mar 9;271(10):751-4 PMID: 8093138
  204. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells.
    Nature. 2007 Aug 23;448(7156):929-33 PMID: 17713535
  205. Prevention of pyelonephritis by immunization with P-fimbriae.
    J Urol. 1984 Mar;131(3):602-7 PMID: 6199527
  206. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract.
    Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16669-74 PMID: 17925449
  207. Tumor necrosis factor alpha- and inducible nitric oxide synthase-producing dendritic cells are rapidly recruited to the bladder in urinary tract infection but are dispensable for bacterial clearance.
    Infect Immun. 2006 Nov;74(11):6100-7 PMID: 16966414
  208. Botanical perspectives on health: of cystitis and cranberries.
    J R Soc Promot Health. 2000 Mar;120(1):52-3 PMID: 10918785
  209. Recurring urinary tract infection: incidence and risk factors.
    Am J Public Health. 1990 Mar;80(3):331-3 PMID: 2305919
  210. Urothelial CD44 facilitates Escherichia coli infection of the murine urinary tract.
    J Immunol. 2006 Nov 15;177(10):7225-32 PMID: 17082640
  211. CCR2 mediates homeostatic and inflammatory release of Gr1(high) monocytes from the bone marrow, but is dispensable for bladder infiltration in bacterial urinary tract infection.
    J Immunol. 2008 Oct 15;181(8):5579-86 PMID: 18832716
  212. Reversible inactivation of bladder surface glycosaminoglycan antibacterial activity by protamine sulfate.
    Infect Immun. 1988 May;56(5):1341-3 PMID: 3281908
  213. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Mol Microbiol. 2005 Jan;55(2):441-55 PMID: 15659162
  214. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin.
    Infect Immun. 1988 Nov;56(11):2774-81 PMID: 3169987
  215. Shear-dependent 'stick-and-roll' adhesion of type 1 fimbriated Escherichia coli.
    Mol Microbiol. 2004 Sep;53(5):1545-57 PMID: 15387828
  216. Polyamine-mediated resistance of uropathogenic Escherichia coli to nitrosative stress.
    J Bacteriol. 2006 Feb;188(3):928-33 PMID: 16428396
  217. Effect of serum albumin on siderophore-mediated utilization of transferrin iron.
    Biochemistry. 1984 May 8;23(10):2122-7 PMID: 6234017
  218. Susceptibility of immunodeficient gene-knockout mice to urinary tract infection.
    J Urol. 1999 Jan;161(1):338-41 PMID: 10037434
  219. Molecular basis of uropathogenic Escherichia coli evasion of the innate immune response in the bladder.
    Infect Immun. 2008 Sep;76(9):3891-900 PMID: 18559433
  220. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group.
    Br J Urol. 1990 Jan;65(1):6-9 PMID: 2178724
  221. Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli.
    Infect Immun. 2007 Nov;75(11):5353-60 PMID: 17724068
  222. Bacterial penetration of bladder epithelium through lipid rafts.
    J Biol Chem. 2004 Apr 30;279(18):18944-51 PMID: 14976212
  223. Characterization of the mouse beta defensin 1, Defb1, mutant mouse model.
    Infect Immun. 2002 Jun;70(6):3053-60 PMID: 12010997
  224. Expression of lactoferrin in the kidney: implications for innate immunity and iron metabolism.
    Kidney Int. 2000 May;57(5):2004-10 PMID: 10792619
  225. Toll-like receptor-4: renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis.
    Kidney Int. 2005 Dec;68(6):2582-7 PMID: 16316333
  226. Actin-gated intracellular growth and resurgence of uropathogenic Escherichia coli.
    Cell Microbiol. 2006 Apr;8(4):704-17 PMID: 16548895
  227. Bladder surface glycosaminoglycans: an epithelial permeability barrier.
    J Urol. 1990 Jan;143(1):139-42 PMID: 1688456
  228. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.
    Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9827-32 PMID: 8790416
  229. Impact of the RNA chaperone Hfq on the fitness and virulence potential of uropathogenic Escherichia coli.
    Infect Immun. 2008 Jul;76(7):3019-26 PMID: 18458066
  230. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract.
    Infect Immun. 2005 Nov;73(11):7644-56 PMID: 16239569
  231. Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism.
    Infect Immun. 2000 Oct;68(10):5869-80 PMID: 10992497
  232. Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors.
    J Biol Chem. 2001 Mar 30;276(13):9924-30 PMID: 11134021
  233. Association of human leucocyte antigen phenotype with vaccine efficacy in patients receiving vaginal mucosal immunization for recurrent urinary tract infection.
    Vaccine. 1999 Jan;17(2):169-71 PMID: 9987151
  234. Extrathymic pathways of T-cell differentiation: a primitive and fundamental immune system.
    Microbiol Immunol. 1993;37(4):247-58 PMID: 8350767
  235. Uropathogenic Escherichia coli strains generally lack functional Trg and Tap chemoreceptors found in the majority of E. coli strains strictly residing in the gut.
    J Bacteriol. 2006 Aug;188(15):5618-25 PMID: 16855252
  236. Protection by a polyvalent vaccine against challenge infection and pyelonephritis.
    Urol Res. 1992;20(2):177-81 PMID: 1553795
  237. [Tissue gamma/delta T cells in experimental urinary tract infection relationship between other immuno-competent cells].
    Kansenshogaku Zasshi. 1994 Dec;68(12):1498-511 PMID: 7876672
  238. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli.
    J Urol. 1997 Mar;157(3):1127-9 PMID: 9072556
  239. Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation.
    Mol Microbiol. 2001 Apr;40(1):37-51 PMID: 11298274
  240. Intracellular bacterial biofilm-like pods in urinary tract infections.
    Science. 2003 Jul 4;301(5629):105-7 PMID: 12843396
  241. P fimbria-specific B cell responses in patients with urinary tract infection.
    J Infect Dis. 2003 Dec 15;188(12):1885-91 PMID: 14673769
  242. Recognition by gamma/delta T cells.
    Annu Rev Immunol. 1996;14:511-32 PMID: 8717523
  243. Role of urothelial surface mucoprotein in intrinsic bladder defense.
    Urology. 1977 May;9(5):526-33 PMID: 324090
  244. Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled.
    J Biol Chem. 2007 Jul 20;282(29):21259-67 PMID: 17504765
  245. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria.
    J Infect Dis. 2007 Aug 1;196(3):475-84 PMID: 17597463
  246. Macrophage inflammatory protein-2, neutrophil recruitment and bacterial persistence in an experimental mouse model of urinary tract infection.
    Microbes Infect. 2004 Nov;6(14):1326-32 PMID: 15555540
  247. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron.
    Nature. 2004 Dec 16;432(7019):917-21 PMID: 15531878
  248. Mucosal immunization with iron receptor antigens protects against urinary tract infection.
    PLoS Pathog. 2009 Sep;5(9):e1000586 PMID: 19806177
  249. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins.
    Nat Med. 2008 Apr;14(4):399-406 PMID: 18327267
  250. Enhancement of cytokine production and natural killer activity by an Escherichia coli extract.
    Onkologie. 1989 Jun;12 Suppl 3:22-5 PMID: 2514401
  251. Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesin.
    Infect Immun. 2005 Jan;73(1):627-31 PMID: 15618205
  252. Role of surface mucin in primary antibacterial defense of bladder.
    Urology. 1977 Jan;9(1):48-52 PMID: 831354
  253. Inhibitors of bacterial adherence to urothelium.
    Invest Urol. 1980 Jul;18(1):40-2 PMID: 7410011
  254. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation.
    Nature. 2009 Mar 5;458(7234):78-82 PMID: 19262671
  255. Comparison of Escherichia coli fimbrial antigen F7 with type 1 fimbriae.
    Infect Immun. 1980 Feb;27(2):657-66 PMID: 6103872
  256. Serology of Escherichia coli fimbriae.
    Prog Allergy. 1983;33:80-105 PMID: 6131427
  257. Endotoxin-induced shedding of viable uroepithelial cells is an antimicrobial defense mechanism.
    Infect Immun. 1988 Jun;56(6):1615-7 PMID: 3286502
  258. Urinary tract infection in iNOS-deficient mice with focus on bacterial sensitivity to nitric oxide.
    Am J Physiol Renal Physiol. 2003 Jan;284(1):F22-31 PMID: 12494944
  259. CD14- and Toll-like receptor-dependent activation of bladder epithelial cells by lipopolysaccharide and type 1 piliated Escherichia coli.
    Infect Immun. 2003 Mar;71(3):1470-80 PMID: 12595465
  260. Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries.
    J Infect Dis. 1985 Dec;152(6):1107-13 PMID: 3905979
  261. Rapid up-regulation of endothelial nitric-oxide synthase in a mouse model of Escherichia coli lipopolysaccharide-induced bladder inflammation.
    J Pharmacol Exp Ther. 2004 Aug;310(2):452-8 PMID: 15082754
  262. Enterobactin: an archetype for microbial iron transport.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3584-8 PMID: 12655062
  263. The pathogen-associated iroA gene cluster mediates bacterial evasion of lipocalin 2.
    Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16502-7 PMID: 17060628
  264. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
    Science. 1998 Sep 11;281(5383):1680-3 PMID: 9733516
  265. Fimbrial lectins influence the chemokine repertoire in the urinary tract mucosa.
    Kidney Int. 2007 Apr;71(8):778-86 PMID: 17228365
  266. A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells.
    PLoS Pathog. 2007 Apr;3(4):e60 PMID: 17465679
  267. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC.
    J Infect Dis. 2000 May;181(5):1753-4 PMID: 10823778
  268. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation.
    Infect Immun. 2007 Jan;75(1):52-60 PMID: 17074856
  269. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections.
    J Urol. 2003 Sep;170(3):867-9 PMID: 12913718
  270. Immunization against urinary tract infection with a multi-valent vaginal vaccine.
    J Urol. 1991 Jul;146(1):223-6 PMID: 2056594
  271. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.
    Science. 1997 Apr 25;276(5312):607-11 PMID: 9110982
  272. Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection.
    Eur J Immunol. 2006 Feb;36(2):267-77 PMID: 16385628
  273. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial.
    J Urol. 2007 Apr;177(4):1349-53; quiz 1591 PMID: 17382730
  274. Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis.
    Infect Immun. 2006 Sep;74(9):5106-13 PMID: 16926402
  275. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli.
    Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17020-4 PMID: 12471157
  276. Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice.
    J Antimicrob Chemother. 2005 Mar;55(3):383-6 PMID: 15681580
  277. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study.
    J Urol. 1993 Sep;150(3):917-21 PMID: 8345609
  278. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.
    Science. 1998 Dec 11;282(5396):2085-8 PMID: 9851930
  279. Lactoferrin: structure, function and applications.
    Int J Antimicrob Agents. 2009 Apr;33(4):301.e1-8 PMID: 18842395
  280. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli.
    Infect Immun. 2007 Apr;75(4):1916-25 PMID: 17145948
  281. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women.
    Br J Obstet Gynaecol. 1998 Apr;105(4):403-7 PMID: 9609266
  282. Interleukin-8 receptor knockout mice have subepithelial neutrophil entrapment and renal scarring following acute pyelonephritis.
    J Infect Dis. 2000 Dec;182(6):1738-48 PMID: 11069247
  283. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.
    Infect Immun. 2003 Dec;71(12):7164-9 PMID: 14638809
  284. P-fimbriae trigger mucosal responses to Escherichia coli in the human urinary tract.
    Cell Microbiol. 2001 Apr;3(4):255-64 PMID: 11298649
  285. Antibody-secreting cells in acute urinary tract infection as indicators of local immune response.
    J Infect Dis. 1994 May;169(5):1023-8 PMID: 8169386
  286. Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection.
    Infect Immun. 2006 Feb;74(2):1387-93 PMID: 16428790
  287. Lipopolysaccharide-responder and nonresponder C3H mouse strains are equally susceptible to an induced Escherichia coli urinary tract infection.
    Infect Immun. 1996 Apr;64(4):1369-72 PMID: 8606102
  288. Interleukin-6 response to deliberate colonization of the human urinary tract with gram-negative bacteria.
    Infect Immun. 1991 Jan;59(1):421-7 PMID: 1987054
  289. Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis.
    J Clin Invest. 1985 Feb;75(2):347-60 PMID: 2857730
  290. Studies on the immunogenicity of an Escherichia coli extract after oral application in mice.
    Arzneimittelforschung. 1997 Aug;47(8):980-5 PMID: 9296288
  291. Tumour necrosis factor and cancer.
    Nat Rev Cancer. 2009 May;9(5):361-71 PMID: 19343034
  292. Secretory immunoglobulin A and G antibodies prevent adhesion of Escherichia coli to human urinary tract epithelial cells.
    Infect Immun. 1978 Dec;22(3):790-7 PMID: 83303
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
1098-5522
DOI
10.1128/IAI.01000-09
Published
2010-02-00
Epub
2009-00-16
Pages
568-85
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC2812207
Subset
IM
External Links
PubMed source DOI: 10.1128/IAI.01000-09 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2